William M Lennox

7297705, Nov 20, 2007

Aug 19, 2004

10/922678

Ronald Charles Bernotas - Royersford PA, US
Derek Cecil Cole - New City NY, US
William Joseph Lennox - South Plainfield NJ, US

Wyeth - Madison NJ

A01N 43/42
A61K 31/44

514300

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.

7585876, Sep 8, 2009

Nov 16, 2007

11/941479

Ronald Charles Bernotas - Royersford PA, US
Derek Cecil Cole - New City NY, US
William Joseph Lennox - South Plainfield NJ, US

Wyeth - Madison NJ

A01N 43/42
A61K 31/44

514300

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.

20120202763, Aug 9, 2012

May 27, 2010

13/321257

Neil Almstead - Princeton NJ, US
Tamil Arasu - Edison NJ, US
Soongyu Choi - Skillman NJ, US
Jeffrey Allen Campbelll - Hilton Head Island SC, US
Donald Corson - Erie CO, US
Thomas W. Davis - South Orange NJ, US
Jason D. Graci - Scranton PA, US
Zhengxian Gu - Princeton NJ, US
Peter Seong Woo Hwang - Edison NJ, US
William Lennox - Bedminster NJ, US
Harry H. Miao - Wellesley MA, US
Langdon Miller - Seatle WA, US
Young-Choon Moon - Belle Mead NJ, US
Hongyan Qi - Plainsboro NJ, US
Christopher Trotta - Somerset NJ, US
Marla L. Weetall - Morristown NJ, US

PTC THERAPEUTICS, INC - South Plainfield NJ

A61K 31/437
A61K 31/496
A61K 31/5377
A61K 31/506
A61K 31/541
A61K 31/53
A61K 31/497
A61P 35/00
A61P 31/12
A61P 19/02
A61P 37/00
A61P 3/04
A61P 17/06
A61P 9/10
A61P 27/02
A61P 27/06
A61P 27/14
A61P 3/02
A61P 29/00
A61P 11/00
A61P 13/12
A61P 9/12
A61P 17/02
A61P 1/04
A61P 31/22
A61P 33/02
A61P 17/12
A61P 9/00
A61P 7/06
A61P 19/04
A61P 31/04
A61P 27/10
A61P 31/14
A61P 31/16
A61P 31/20
A61P 31/18
C12N 5/09
C12N 5/071
C07H 19/056
A61K 31/7056
C07F 7/10
A61K 31/695
A61P 17/10
C07D 471/04

514 43, 546 85, 544361, 544126, 544331, 544319, 514292, 51425303, 5142328, 514275, 514269, 544 586, 5142282, 544122, 544212, 514245, 544405, 51425505, 435366, 435375, 546 87, 536 287, 544182, 514242, 546 14, 514 63

Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.